LSDI Overview

Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.

Wall Street analysts forecast LSDI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSDI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lucy Scientific Discovery Inc revenue for the last quarter amounts to 10.00K USD, decreased % YoY.

Lucy Scientific Discovery Inc. EPS for the last quarter amounts to -1.48 USD, increased 1544.44 % YoY.

Lucy Scientific Discovery Inc (LSDI) has 0 emplpoyees as of January 31 2026.

Today LSDI has the market capitalization of 1.00M USD.